about
Detection and follow up of exocrine pancreatic insufficiency in cystic fibrosis: a review.Comparative bone status assessment by dual energy X-ray absorptiometry, peripheral quantitative computed tomography and quantitative ultrasound in adolescents and young adults with cystic fibrosis.Acute pancreatitis complicated with choledochal duct rupture.Anal canal duplication in an 11-year-old-child.Vitamin K, an update for the paediatrician.Clinical practice: neonatal cholestasis.ESPGHAN and NASPGHAN Report on the Assessment of Exocrine Pancreatic Function and Pancreatitis in Children.Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO).Paediatric Crohn Disease: Disease Activity and Growth in the BELCRO Cohort After 3 Years Follow-up.Faecal leukocyte esterase activity is an alternative biomarker in inflammatory bowel disease.Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.Colonic transit time in mentally retarded persons.Colon transit time in healthy children and adolescents.Colon enemas for fecal incontinence in patients with spina bifida.C-ANCA/proteinase 3-positive colitis in children: a distinctive form of inflammatory bowel disease or vasculitis with colitis as initial presentation?Proteolysis is a confounding factor in the interpretation of faecal calprotectin.High-dose omeprazole in esophagitis with stenosis after surgical treatment of esophageal atresia.Achromobacter xylosoxidans induced bronchiolitis obliterans in cystic fibrosis.Nutritional support in children with neurodevelopmental disabilities. Proceedings Bespghan Meeting, Ghent December 2011.Cystic fibrosis: an unusual cause of chronic pancreatitis.Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.Epstein-Barr virus related lymphoma in inflammatory bowel disease.Clinical characteristics of food allergy post paediatric liver transplantation.Clinical effects of probiotics in cystic fibrosis patients: A systematic review.Cystic fibrosis presenting as diabetes insipidus unresponsive to desmopressin.Development and validation of a spina bifida-specific pediatric quality of life questionnaire: the Spina Bifida Pediatric Questionnaire, SBPQ.Colon transit time and anorectal manometry in children and young adults with spina bifida.Profile of pediatric Crohn's disease in Belgium.Proposal for An Algorithm for Screening for Undernutrition in Hospitalized Children.The effect of enteral tube feeding in cystic fibrosis: A registry based study.Quantitative bone ultrasound at the distal radius in adults with cystic fibrosis.The course of anaemia in children and adolescents with Crohn's disease included in a prospective registry.Anaphylactic shock as a single presentation of Echinococcus cyst.Nutrition and pancreatic enzyme intake in patients with cystic fibrosis with distal intestinal obstruction syndrome.Thoracic duct ligation as treatment of chylothorax due to vena cava superior thrombosis.Solid food refusal as the presenting sign of vitamin B12 deficiency in a breastfed infant.Faecal incontinence due to atrophy of the anal sphincter in myotonic dystrophy: a case report.Upper gastrointestinal tract bleeding management: Belgian guidelines for adults and children.Mesalazine interstitial nephritis presenting as colitis ulcerosa exacerbation.Normalisation of colon transit time in a spina bifida adolescent after neurosurgery for retethering.
P50
Q34020830-E59B8F05-A5B6-492C-825E-894A5AFA1E28Q34084223-BA44E8E3-18C3-4EF6-914F-4E939AC24702Q35953077-02E85C78-7751-42B9-B5AF-1FF38FF978F0Q37208834-B38DACEC-568A-40EF-B143-978760F1F1D3Q37316661-643B0216-FC1B-47D0-897E-8EF8227BB8C9Q37830353-C8B625FF-0832-4D08-B370-1CF0AAD9BD33Q38443880-830DA949-FBB3-4965-8DEB-36497DD16368Q38684176-780466F8-CB4A-4A17-B71A-F156E0DC6D59Q40032427-516487DF-24AE-4D7A-9078-80BDC540F2ECQ41059819-D6D1D70F-4B82-450D-93F0-A6EE8017E14DQ42606049-9BB2AA13-6581-4C97-8920-85EEDD58AFEFQ43315525-25E9A4B6-81ED-457C-95CA-BD416F38B62BQ43361719-BC6768BC-26EE-4B47-946F-DEB82A843D7EQ43413491-16D19804-13F8-427C-9FAB-6F8B63E68220Q43452522-A5FCAF33-CE22-4826-B3DA-330B245D351EQ43540457-48E5C404-5054-48A2-8DEF-3ACD776BB38BQ43723814-3EEA7994-8D10-40BE-9933-40F8A5277EC3Q43880447-DC589010-24B1-4AD9-9690-50C5C55FB560Q44527881-C070AFE8-D472-4DF8-A32F-DB4154EE6775Q44656509-28520771-CD70-49EB-BCA0-2152FB8AA13CQ44914293-A460B5CE-B2F6-4077-8D2B-0732C46CBF54Q45395963-43518C75-3619-494D-9A82-4A1298A2ACDEQ45956550-40EE908F-B0E0-4B7A-B4C9-DEBA4E1B4335Q46262539-1704936C-9662-4B91-BCF4-7A3D04A8E3BEQ46854537-6F0699FD-1AFC-4FD7-AE92-ADDA00D3F7C4Q47966902-EF8B3946-8107-49F8-86F8-5180A7F5EB57Q48551348-5164928E-8C45-484E-B1D7-EFC32A0CAA01Q48552599-D0CFF30B-2F44-49C6-8D05-C80BAC99FEE8Q48962717-B8427710-7918-4B7A-AD2D-6BDC981F7A05Q49028433-E062DF37-8D44-489A-A1F9-E64C25CD7FBDQ49033963-FF7E3DD6-E64F-4037-BBAC-66B46CAE235BQ49039244-A0576008-26A6-4DC5-A706-165395420D18Q49041728-B8A34FE8-ABC4-47CB-9E74-7B9154412F4DQ49041963-931E6BE1-094E-43E4-98B9-8A5D54A0D1ADQ49051060-E90009C5-F079-4EE2-8334-023915A24491Q49054310-82F9FB7D-CB88-458A-8A2E-54AD4A953524Q49060941-9A502956-F93C-470A-A32A-A06652116E0DQ49060964-D2823456-1944-4F3D-B9C6-B794B3B584C7Q49067474-23DA1564-E459-4CED-A7EC-851A5B100A31Q49074099-F688E1B1-BEE2-4D98-9ECB-1B9B1E399D90
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stephanie Van Biervliet
@ast
Stephanie Van Biervliet
@en
Stephanie Van Biervliet
@es
Stephanie Van Biervliet
@nl
Stephanie Van Biervliet
@sl
type
label
Stephanie Van Biervliet
@ast
Stephanie Van Biervliet
@en
Stephanie Van Biervliet
@es
Stephanie Van Biervliet
@nl
Stephanie Van Biervliet
@sl
prefLabel
Stephanie Van Biervliet
@ast
Stephanie Van Biervliet
@en
Stephanie Van Biervliet
@es
Stephanie Van Biervliet
@nl
Stephanie Van Biervliet
@sl
P106
P108
P1153
6602271858
P2038
Stephanie_Biervliet
P21
P31
P496
0000-0001-5609-3726